Modasomil (Modafinil)

Modafinil, the active ingredient in Modasomil, is a eugeroic presented as an oral tablet for oral use. It promotes wakefulness and is prescribed for sleep‑related disorders such as narcolepsy, obstructive sleep apnea‑related excessive daytime sleepiness, and shift‑work sleep disorder.

GNH USA supplies Modasomil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modasomil is a central nervous system stimulant indicated for conditions that cause excessive daytime sleepiness. - Narcolepsy: reduces daytime sleep attacks and improves alertness. - Obstructive sleep apnea‑related excessive daytime sleepiness: mitigates residual sleepiness despite optimal apnea treatment. - Shift work sleep disorder: helps maintain wakefulness during scheduled work hours.

Modasomil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Insomnia: difficulty initiating or maintaining sleep. - Dry mouth: reduced salivation. - Anxiety: feelings of nervousness or tension. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Rash or Stevens‑Johnson syndrome: severe skin reactions. - Psychiatric symptoms: hallucinations or mania. - Cardiovascular events: chest pain or arrhythmia. - Liver injury: elevated transaminases. - Allergic reaction: swelling, difficulty breathing.

Before prescribing Modasomil, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate history of hypertension or arrhythmias. - Psychiatric evaluation: screen for prior psychosis or severe anxiety. - Liver function: monitor hepatic enzymes in patients with liver disease. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Drug dependence: assess risk of misuse in individuals with substance‑use history. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Modasomil can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase modafinil plasma levels. - CYP2C19 inhibitors (e.g., fluvoxamine): can raise exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Oral contraceptives: modafinil may reduce hormonal efficacy; consider alternative contraception. - Antidepressants (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Antihypertensives: possible reduction in blood pressure control. - Caffeine or other stimulants: additive central nervous system stimulation.